Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)

Report documents

1. Extract to commission A12-02 (emtricitabine/rilpivirine/tenofovir)

   Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)

   published on

   05.07.2012

   Document type

   PDF document, 350 kB, EN, not accessible

   Download file : Extract to commission A12-02 (emtricitabine/rilpivirine/tenofovir) (PDF document, 350 kB, EN, not accessible)
2. Addendum

   Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)

   published on

   05.07.2012

   Document type

   PDF document, 330 kB, DE, not accessible

   Download file : Addendum (PDF document, 330 kB, DE, not accessible)

Press releases

Project details

Project no.

A12-10

Commission

Commission awarded on 07.06.2012 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Immune system and infections

Note

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Connected Projects

1. Dossier assessment

   Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

   Project no.

   A12-02

   Last updated

   16.04.2012

   Status: Commission completed